logo-loader

CEO: Summit Therapeutics’ ridinilazole generating “huge interest” from industry experts

Last updated: 15:00 12 Apr 2016 BST, First published: 09:00 12 Apr 2016 BST

Glyn Edwards, chief executive of Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT) says the results from its Phase II trial for its treatment for super-bug C- diff was “just about as good as we could have expected and dreamed of,” adding that it is generating “a huge amount of interest” from C-difficile experts.

Clostridium difficile, or C-diff, is caused after damage to the microbiome but patients can get a double whammy, as using broad spectrum antibiotics can further damage the microbiome.

Summit said the findings show a reduced recurrence rate and a superior rate of sustained clinical response in patients with C-diff receiving its treatment ridinilazole, compared with those receiving the standard of care, vancomycin.

Oriole Resources outlines 2023 achievements and future exploration plans

Oriole Resources PLC (AIM:ORR) CEO Tim Livesey and chief financial officer Bob Smeeton join Proactive's Stephen Gunnion with details of the company's 2023 financial and operational performance. Livesey highlighted successful exploration programs in Cameroon, at the Bibemi and Mbe projects,...

42 minutes ago